Few areas of women's health have shifted as much in recent years as breast cancer screening. The old rules were simple, if not always right: monthly self-exams, annual mammograms starting at forty. The current picture is more nuanced, more personalized, and, for anyone trying to make decisions in the exam room, more confusing.
Understanding what the major bodies actually recommend, and what has quietly changed, helps you have a better conversation with your clinician rather than a shorter one.
Self-exams: what changed and why
For decades, women were taught structured monthly breast self-exams. Large trials, notably in Shanghai and Russia, later showed that formal self-exams did not reduce breast cancer mortality but did increase biopsies of benign findings. The U.S. Preventive Services Task Force does not currently recommend teaching formal self-exam.
That is not the same as saying you should ignore your breasts. Most major organizations now use the language of breast self-awareness: knowing how your breasts normally look and feel, and reporting changes without a fixed schedule or checklist.
Changes worth raising with a clinician include:
- A new lump or thickening, in the breast or armpit
- Skin dimpling, puckering, or a rash that does not resolve
- Nipple retraction, or spontaneous, one-sided nipple discharge, especially bloody
- Persistent, focal breast pain in one spot
- A change in size or shape of one breast relative to the other
Most of these findings turn out to be benign. That does not make them not worth checking.
Mammograms: the moving goalposts
In 2024, the U.S. Preventive Services Task Force updated its recommendation to begin biennial screening mammography at age forty for average-risk women, down from fifty. The American College of Obstetricians and Gynecologists and the American Cancer Society have long supported earlier starting ages as well, though they differ on frequency and stopping age.
For most average-risk women, this now means:
- Begin screening at forty
- Continue at least until seventy-four, with individualized decisions beyond
- Discuss annual versus biennial timing based on your preferences and risk
Risk changes the calculus. A strong family history, a known BRCA1 or BRCA2 mutation, prior chest radiation, dense breasts, or certain benign biopsy findings may warrant earlier screening, supplemental MRI, or genetic counseling. Do not assume your primary care visit will surface these questions unprompted.
Dense breasts and the newer conversation
Roughly forty percent of women aged forty and older have dense breast tissue, which both increases breast cancer risk and reduces the sensitivity of mammography. As of 2024, the FDA requires all U.S. mammography facilities to notify patients about their breast density. What that notification does not always include is what to do next.
A density notification is not a diagnosis. It is a prompt for a conversation about whether supplemental screening might help you.
Options vary by risk level and access, and may include tomosynthesis, ultrasound, or MRI. The evidence base is strongest for high-risk women, less settled for average-risk women with dense tissue alone.
Questions worth bringing to the visit
A short list you can adapt:
- Based on my personal and family history, what is my estimated breast cancer risk?
- Do I have dense breasts on my most recent mammogram, and does that change what I should do?
- Am I a candidate for genetic counseling or BRCA testing?
- If a finding needs follow-up, what is the plan, and who will call me?
- When should I come back, and what changes should prompt an earlier visit?
Bring paper. Screening algorithms are individualized enough now that you will not remember it all.
The bottom line
Formal monthly self-exams have been replaced by the softer concept of breast self-awareness, and mammography now generally starts at forty rather than fifty. Dense breasts and family history change the picture. The most useful thing you can do is know your own baseline, know your risk category, and ask direct questions about the plan rather than accepting a generic script.